as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹437.35
Change
+2.55 (0.59%)
Open
₹434.8
Prev. Close
₹434.8
Day High
₹438.95
Day Low
₹430.15
Volume Analysis
Traded
219,151
Delivered
106,280
Delivery %
48.5%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (21.0%)
Weaknesses (2)
- •Low return on equity (7.78%)
- •Promoter holding is falling
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹449.61 | ₹444.28 | ₹440.81 | ₹435.48 | ₹432.01 | ₹426.68 | ₹423.21 |
| Fibonacci | ₹444.28 | ₹440.92 | ₹438.84 | ₹435.48 | ₹432.12 | ₹430.04 | ₹426.68 |
| Camarilla | ₹439.77 | ₹438.96 | ₹438.16 | ₹435.48 | ₹436.54 | ₹435.74 | ₹434.93 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-32.74%
1 Week
-2.33%
1 Month
+16.18%
3 Months
+7.39%
6 Months
-5.3%
1 Year
-31.08%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹145.68
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
4.05%
Net margin 5.28% × asset turnover 0.56x × equity multiplier 1.37x
Company Overview
Sector
Healthcare
Market Cap
₹17,935 Cr
P/E (TTM)
67.5
ROE
7.78%
Book Value
₹120.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.
TopFund Analysis
Syngene International Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 55/100. The strongest factor is Financial Strength (100/100), while Growth (21/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (21.0%); low return on equity (7.78%); promoter holding is falling. FII holding has been falling.
TopFund Score — Fundamentals Quality
55/100 — AverageData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Stock is trading at 3.69 times its book value
- −The company has delivered a poor sales growth of 11.4% over past five years.
- −Company has a low return on equity of 10.2% over last 3 years.
- −Dividend payout has been low at 12.0% of profits over last 3 years
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Syngene schedules analyst/investor meetings with several institutions from 17-24 Nov 2026.
Syngene uploaded Q2 FY2027 earnings conference call transcript on its website.
Audio recording of Syngene’s Q2 FY27 earnings call uploaded on October 28, 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 910 | 854 | 917 | 790 | 891 | 944 | 1,018 | 874 | 911 | 917 | 1,036 | 736 | 833 |
| Expenses + | 656 | 622 | 600 | 620 | 646 | 660 | 674 | 668 | 711 | 708 | 733 | 645 | 685 |
| Operating Profit | 254 | 232 | 317 | 170 | 245 | 284 | 344 | 206 | 200 | 209 | 303 | 91 | 147 |
| OPM % | 28.0% | 27.0% | 35.0% | 22.0% | 27.0% | 30.0% | 34.0% | 24.0% | 22.0% | 23.0% | 29.0% | 12.0% | 18.0% |
| Other Income + | 14 | 26 | 16 | 50 | 16 | 18 | 19 | 18 | 15 | -55 | 16 | 12 | 21 |
| Interest | 13 | 11 | 13 | 12 | 13 | 12 | 16 | 12 | 13 | 12 | 12 | 10 | 10 |
| Depreciation | 105 | 108 | 111 | 107 | 111 | 109 | 106 | 111 | 116 | 114 | 112 | 112 | 112 |
| Profit before tax | 151 | 138 | 209 | 101 | 137 | 181 | 240 | 101 | 85 | 28 | 196 | -19 | 47 |
| Tax % | 23.0% | 19.0% | 10.0% | 25.0% | 23.0% | 27.0% | 24.0% | 14.0% | 21.0% | 47.0% | 25.0% | -53.0% | 31.0% |
| Net Profit + | 116 | 112 | 189 | 76 | 106 | 131 | 183 | 87 | 67 | 15 | 148 | -9 | 32 |
| EPS in Rs | 3 | 3 | 5 | 2 | 3 | 3 | 5 | 2 | 2 | 0 | 4 | 0 | 1 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 18 | 9 | -8 | -2 | -2 | 11 | 11 | 11 | 2 | -3 | 2 | -16 | -9 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,423 | 1,826 | 2,012 | 2,184 | 2,604 | 3,193 | 3,489 | 3,642 | 3,739 | 3,522 |
| Expenses + | 949 | 1,289 | 1,394 | 1,507 | 1,861 | 2,251 | 2,472 | 2,598 | 2,817 | 2,772 |
| Operating Profit | 474 | 537 | 618 | 678 | 743 | 942 | 1,017 | 1,045 | 921 | 751 |
| OPM % | 33.0% | 29.0% | 31.0% | 31.0% | 29.0% | 30.0% | 29.0% | 29.0% | 25.0% | 21.0% |
| Other Income + | 53 | 75 | 153 | 94 | 75 | 63 | 77 | 101 | -9 | -6 |
| Interest | 23 | 32 | 35 | 28 | 24 | 45 | 47 | 53 | 49 | 44 |
| Depreciation | 131 | 164 | 219 | 274 | 310 | 366 | 426 | 433 | 453 | 449 |
| Profit before tax | 372 | 415 | 517 | 469 | 484 | 594 | 621 | 660 | 411 | 252 |
| Tax % | 18.0% | 20.0% | 20.0% | 14.0% | 18.0% | 22.0% | 18.0% | 25.0% | 23.0% | — |
| Net Profit + | 305 | 332 | 412 | 405 | 396 | 464 | 510 | 496 | 317 | 186 |
| EPS in Rs | 8 | 8 | 10 | 10 | 10 | 12 | 13 | 12 | 8 | 5 |
| Dividend Payout % | 7.0% | 3.0% | 0.0% | 0.0% | 10.0% | 11.0% | 10.0% | 10.0% | 16.0% | — |
| Sales growth | — | 28 | 10 | 9 | 19 | 23 | 9 | 4 | 3 | -6 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 1,520 | 1,768 | 1,776 | 2,421 | 2,897 | 3,217 | 3,856 | 4,324 | 4,436 | 4,455 |
| Borrowings + | 787 | 813 | 773 | 893 | 1,022 | 815 | 555 | 578 | 458 | 507 |
| Other Liabilities + | 681 | 922 | 1,214 | 1,169 | 1,245 | 1,398 | 1,339 | 1,491 | 1,757 | 1,292 |
| Total Liabilities | 3,189 | 3,704 | 4,163 | 4,883 | 5,564 | 5,831 | 6,152 | 6,796 | 7,055 | 6,658 |
| Fixed Assets + | 1,030 | 1,377 | 2,020 | 2,201 | 2,393 | 2,667 | 2,850 | 2,802 | 3,000 | 2,880 |
| CWIP | 155 | 274 | 234 | 237 | 346 | 177 | 838 | 1,266 | 1,046 | 1,141 |
| Investments | 158 | 716 | 776 | 702 | 1,034 | 918 | 548 | 647 | 741 | 610 |
| Other Assets + | 1,846 | 1,337 | 1,133 | 1,743 | 1,790 | 2,069 | 1,916 | 2,081 | 2,268 | 2,028 |
| Total Assets | 3,189 | 3,704 | 4,163 | 4,883 | 5,564 | 5,831 | 6,152 | 6,796 | 7,055 | 6,658 |
| Equity Capital | 200 | 200 | 400 | 400 | 401 | 401 | 402 | 402 | 403 | 404 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 446 | 630 | 677 | 701 | 581 | 824 | 1,042 | 1,168 | 915 |
| Cash from Investing Activity + | -349 | -646 | -424 | -629 | -611 | -653 | -494 | -744 | -839 |
| Cash from Financing Activity + | -79 | -72 | -226 | 58 | -31 | -342 | -551 | -142 | -215 |
| Net Cash Flow | 18 | -88 | 28 | 130 | -62 | -172 | -4 | 281 | -138 |
| Free Cash Flow | 82 | 47 | 34 | 255 | 105 | 305 | 553 | 398 | 547 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 111 | 135 | 127 | 116 | 92 | 102 | 115 | 123 | 107 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Others | 0.32% | 0.31% | 0.43% | 0.34% | 0.29% | 0.29% | 0.31% | 0.3% | 0.29% | 0.29% | 0.43% | 0.41% |
| Public | 9.07% | 8.18% | 7.44% | 6.74% | 6.79% | 5.99% | 6.45% | 6.08% | 6.22% | 6.69% | 7.15% | 7.55% |
| Promoters | 54.79% | 54.79% | 54.72% | 54.72% | 52.74% | 52.74% | 52.68% | 52.68% | 52.68% | 52.68% | 52.59% | 52.59% |
| FII | 21.2% | 20.92% | 20.64% | 20.72% | 20.65% | 19.47% | 16.51% | 16.31% | 14.96% | 13.91% | 11.82% | 10.13% |
| DII | 14.63% | 15.8% | 16.78% | 17.49% | 19.52% | 21.5% | 24.05% | 24.62% | 25.83% | 26.44% | 28.01% | 29.31% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Syngene International Ltd (this stock) | 17,935 | 67.5 | 3.7 | 7.78% |
| Caplin Point Lab Ltd. | 17,863 | 25.9 | 4.58 | 20.9% |
| Alivus Life Sciences Ltd | 17,803 | 50.6 | — | — |
| Pfizer Ltd | 17,601 | 115.0 | 12.74 | 19.8% |
| Cohance Lifesciences Ltd | 17,511 | 359.0 | 4.49 | 4.89% |
| Dr Agarwals Health Care L | 17,460 | 97.5 | 7.8 | 6.41% |
| Eris Lifesciences Limited | 18,448 | 24.7 | 4.45 | 18.7% |
Which Mutual Funds Hold Syngene International Ltd?
Frequently Asked Questions about Syngene International Ltd
Syngene International Ltd (SYNGENE) closed at ₹437.35 on NSE on 19 November 2026, up 2.55 (0.59%) from the previous close.
Syngene International Ltd trades on the NSE (National Stock Exchange of India) under the symbol SYNGENE.
Syngene International Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 67.5.
Syngene International Ltd has a dividend yield of 0.28%.
Syngene International Ltd's 52-week high is ₹679.0 and its 52-week low is ₹344.0.
Syngene International Ltd has a market capitalisation of ₹17,935 crore.
Syngene International Ltd has a TopFund Quality Score of 55/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Syngene International Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.